Amiodarone, a class III antiarrhythmic, has been widely used to treat both ventricular and supraventricular arrhythmias. Despite the multitude of side-effects seen with this drug, no case of amiodarone anaphylaxis (confirmed by mast cell tryptase levels and skin testing) has been reported in the medical literature. We report a case of anaphylaxis to intravenous amiodarone in a 77-year-old patient.
Amiodarone has many side-effects involving most of the body systems, which often limit its use. Most of these adverse effects are dose-related and cumulative, hence they are usually seen in the setting of long-term oral administration. Cardiovascular side-effects (symptomatic bradycardia, ventricular arrhythmias, and worsening congestive heart failure), although less common, are potentially the most serious observed with an intravenous (IV) dose. However, anaphylaxis has not been previously reported in the medical literature.
CASE REPORT
A 77-year-old female presented to the Emergency Department with sudden onset of palpitations and the sensation of chest heaviness. Her past medical history included hypertension, scoliosis, and mild memory loss. There was no history of ischaemic heart disease. Her medications included aspirin, alprazolam and candesartan. She was allergic to penicillin and sulphamethoxazole. On clinical examination she had an irregular pulse rate of 150 to 180 beats per minute. Blood pressure was 117/78 mmHg, and oxygen saturation was normal on high flow oxygen. Chest X-ray was unremarkable and there was no clinical or radiological evidence of cardiac failure. Her electrocardiogram (ECG) confirmed atrial fibrillation with a rapid ventricular response rate. There was no ST segment elevation or depression. A diagnosis of fast atrial fibrillation with resulting ischaemic chest pain was made. An IV infusion of amiodarone 300 mg was commenced. After three minutes, the patient complained of swelling in her throat and a generalized skin rash was noted on her body. She became cold, clammy and hypotensive. Blood pressure became unrecordable and ECG confirmed an asystolic cardiac arrest. The amiodarone infusion was stopped and cardiopulmonary resuscitation was commenced. She was resuscitated with a crystalloid fluid infusion, intravenous adrenaline (1 mg) and hydrocortisone (250 mg). She was intubated and ventilated with 100% oxygen, and after three further boluses of adrenaline, her circulation was restored. Her ECG showed sinus rhythm at 88 beats per minute with unifocal ventricular ectopics. Routine bloods, including samples for mast cell tryptase, were collected. A central venous catheter and arterial line were inserted and her circulation was supported with an adrenaline infusion. She was transferred to the intensive care unit where supportive treatment was continued. A second blood sample for mast cell tryptase was collected 4 hours later. The adrenaline infusion was weaned and she was extubated the following morning. She was discharged to a general ward later that day.
Routine biochemistry and haematology as well as serial cardiac enzymes (including troponin) were unremarkable, however mast cell tryptase level was 7.9 ug/l in the first sample and 46.5 ug/l in the second (Lab Reference=0-15 ug/l). This confirmed a possible diagnosis of amiodarone anaphylaxis. Intradermal skin testing 1 was performed six weeks later with normal saline, morphine, and amiodarone (the last two as 1/1000 dilutions). There was a negative skin reaction to normal saline and positive reactions to morphine (40 mm flare) and amiodarone
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An allergy alert was added to the patient's medical record and a letter documenting this was given to the patient. She was also advised to wear a "Medic-Alert" type medallion.
DISCUSSION
Amiodarone is an iodinated benzofuran derivative 2 , used for the treatment of both supraventricular and ventricular arrhythmias. It acts through interference with potassium (class III) 3 , sodium (class I) 4 , and calcium (class IV) 5 . It also has a beta-blocking (class II) 6 effects. However, it is generally considered as a class III antiarrhythmic agent according to the Vaughan-Williams classification. Its role as an antiarrhythmic has been expanding and it is used to treat arrhythmias in a variety of settings (e.g. outpatient, pre-hospital, atrial fibrillation, advanced cardiac life support 7 , and post cardiac surgery 8 ). The major limiting factor in the use of amiodarone is its side-effect profile. Up to 75% of patients have an adverse sideeffect within five years of treatment and 18-37% of patients discontinue it because of these effects 9 . However, most of the effects are dose-related and are seen in the setting of long-term oral therapy. To the authors' best knowledge, no case of amiodarone anaphylaxis, confirmed by mast cell tryptase levels and intradermal skin testing, has been reported in the medical literature. A case of angioedema secondary to chronic amiodarone administration has been reported, but the patient had a negative skin prick test and non-lgE mediated reaction was proposed 10 .
Tryptase is a serine protease present mainly in the secretory granules of human mast cells; with basophils containing 300-700 fold less tryptase. Therefore tryptase levels in the serum are a marker of mast cell activation 11 .
Although elevated mast cell tryptase levels were thought to occur in cardiac arrest due to cardiac causes this was proven not to be the case by Edston et al 12 .
There are two points that need to be made about this case report for the sake of scientific completeness.
The first point is that despite the lack of history of previous exposure to amiodarone which is required for an lgE mediated process we do not think that this can be totally excluded on the basis of history alone (e.g. environmental or other type of exposure to amiodarone analogues).
The other point is the absence of negative control test for intradermal amiodarone to exclude the possibility of false positives.
Despite the abovementioned points we believe that this is the first case of amiodarone anaphylaxis documented in the literature. In view of the expanding use of amiodarone in clinical practice, clinicians should be alerted to this rare but life-threatening side-effect.
